Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Pamplona – page 63

761 clinical trials in Pamplona, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Pamplona at a glance
761
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

761 trials in Pamplona

Open in trial search

Renal cancer metastatic

Not recruiting

Study on Cabozantinib, Nivolumab, and Ipilimumab for Patients with Advanced or Metastatic Kidney Cancer Who Have Not Received Prior Treatment

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Exelixis Inc.

Pancreatic carcinoma metastatic

Not recruiting

Study of Tumor Treating Fields with Atezolizumab, Gemcitabine, and Nab-Paclitaxel for Patients with Metastatic Pancreatic Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Novocure GmbH

Hodgkin's disease

Not recruiting

Study on Early Response to Brentuximab Vedotin and Drug Combination for Advanced Hodgkin Lymphoma Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Plasma cell myeloma

Not recruiting

Study of Belantamab Mafodotin, Carfilzomib, and Dexamethasone for Patients with Relapsed Multiple Myeloma Resistant to Lenalidomide

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Fundacion PETHEMA

Plasma cell myeloma

Not recruiting

Study Comparing Lenalidomide, Bortezomib, Dexamethasone, Isatuximab, and Iberdomide for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Bortezomib
  • Sponsor:Fundacion PETHEMA

Squamous cell carcinoma of head and neck

Not recruiting

Study of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Retifanlimab
  • Sponsor:Incyte Biosciences International S.a.r.l.

Plasma cell myeloma

Not recruiting

Study on Carfilzomib, Lenalidomide, and Dexamethasone for Patients Under 70 with High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Fundacion PETHEMA

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Volrustomig with a Drug Combination for Patients with Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Colorectal cancer metastatic

Not recruiting

Study on Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Associacio Per A La Recerca Oncologica

Plasma cell myeloma

Not recruiting

Study on the Effectiveness of Bortezomib, Melphalan, and Prednisone vs. Carfilzomib, Lenalidomide, and Dexamethasone in Older Adults with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years
  • Substances:Bortezomib
  • Sponsor:Fundacion PETHEMA

Bladder cancer

Not recruiting

Study of Sasanlimab and Sacituzumab Govitecan for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sasanlimab
  • Sponsor:Associacio Per A La Recerca Oncologica

Asthma

Not recruiting

Study on Reducing Asthma Medication with Tezepelumab in Patients Aged 12 to 80 with Severe Asthma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Pamplona

What the registry says about research in the country

01 Oncology Research

Innovative trials exploring treatments for various cancers, including metastatic colorectal cancer, bladder cancer, and prostate cancer. Studies focus on combination therapies and novel treatment approaches.

  • Colorectal Cancer Treatment Studies
  • Prostate Cancer Therapies
  • Blood Cancer Research

Multiple trials evaluating immunotherapies and targeted treatments for improving patient outcomes.

02 Immunology and Inflammation

Research focused on treating autoimmune conditions and inflammatory disorders, including studies on cutaneous lupus erythematosus and atopic dermatitis.

  • Lupus Treatment Studies
  • Dermatological Conditions
  • Immune System Disorders

Evaluating new therapeutic approaches for chronic inflammatory conditions.

03 Respiratory Medicine

Clinical investigations targeting respiratory conditions, including studies on COPD and respiratory viral infections. Research focuses on improving treatment outcomes.

  • COPD Management
  • Respiratory Virus Prevention
  • Nasal Polyps Treatment

Development of innovative therapies for respiratory diseases and infections.

04 Metabolic Disorders

Studies addressing obesity, diabetes, and related metabolic conditions. Research focuses on weight management and blood sugar control.

  • Type 2 Diabetes Treatment
  • Weight Management Therapies
  • Metabolic Disease Research

Investigating new approaches for metabolic disorder management.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.